Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026)

Neurocrine Biosciences filings provide 9 years of Gross Margin readings, the most recent being 97.82% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 70.0% to 97.82% in Q4 2025 year-over-year; TTM through Dec 2025 was 98.18%, a 38.0% decrease, with the full-year FY2025 number at 98.18%, down 38.0% from a year prior.
  • Gross Margin hit 97.82% in Q4 2025 for Neurocrine Biosciences, roughly flat from 98.24% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.93% in Q2 2021 to a low of 76.0% in Q2 2022.
  • Median Gross Margin over the past 5 years was 98.41% (2025), compared with a mean of 97.23%.
  • Biggest five-year swings in Gross Margin: plummeted -2293bps in 2022 and later surged 2146bps in 2023.
  • Neurocrine Biosciences' Gross Margin stood at 98.69% in 2021, then dropped by -1bps to 98.13% in 2022, then grew by 0bps to 98.35% in 2023, then rose by 0bps to 98.52% in 2024, then dropped by -1bps to 97.82% in 2025.
  • The last three reported values for Gross Margin were 97.82% (Q4 2025), 98.24% (Q3 2025), and 98.36% (Q2 2025) per Business Quant data.